Ann Rheum Dis: Long-term efficacy and safety of Sukindan resistance to refractory macauca mucosa and joint phenotypes

The study was designed to assess the efficacy and safety of Sukindan resistance to patients with white plug disease mucosa and joint phenomenades that are resistant to conventional and biological therapyA multicenter retrospective study included 15 patients with white congestion mucosa and joint phenomenades that meet international standards for white sepsis and are resistant to autumn daffodils, disease-improved anti-rheumatic agents, and at least one anti-tumor necrosis factor alpha agentThe minimum follow-up time is set at 6 monthsSix patients with multiple joints received Sukindan 300mg/month treatment, while other cases received Sukindan 150mg/month treatmentPoor control of the disease allows the dose to increase from 150 mg to 300 mg per month and reduces the frequency of administrationThe response was assessed based on a disease activity score of 28 for the number of mouth ulcers and joint performance in the first 28 daysfollow-up for 3 months, nine patients (66.7 per cent) received remission (full or partial) and increased further to 86.7 per cent at six months, 76.9 per cent at 12 months, 90.0 per cent at 18 months and 100.0 per cent after 24 monthsIt is worth noting that all patients with a starting dose of 300 mg/month of Sukin monoantigen reached complete remission in the 6th monthSeven patients (46.7%) were only able to achieve remission if they switched to a higher dosethis study showed that long-term treatment with 150mg and 300mg of sukindan resistance per month was safe and effective for patients with previous treatments for drug-resistant white plug mucosa and joint phenomenadesIt is worth noting that Sukindan is performing better in inducing complete remission of mucous membranes and joints at 300 mg/month, and there are no serious or dose-related adverse reactions